Kalbe Farma Tbk PT Asset Resilience Ratio
Kalbe Farma Tbk PT asset resilience ratio. Kalbe Farma Tbk PT (KLBF) has an Asset Resilience Ratio of 0.46% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kalbe Farma Tbk PT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kalbe Farma Tbk PT (2000–2025)
Asset resilience ratio of Kalbe Farma Tbk PT from 2000 to 2025. This chart shows how Kalbe Farma Tbk PT's Asset Resilience Ratio has changed over time. Read how much debt does Kalbe Farma Tbk PT carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kalbe Farma Tbk PT's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Kalbe Farma Tbk PT balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 0% |
| Short-term Investments | Rp153.40 Billion | 0.46% |
| Total Liquid Assets | Rp153.40 Billion | 0.46% |
Asset Resilience Insights
- Limited Liquidity: Kalbe Farma Tbk PT maintains only 0.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Kalbe Farma Tbk PT Industry Peers by Asset Resilience Ratio
Compare Kalbe Farma Tbk PT's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
Kalbe Farma Tbk PT Asset Resilience Ratio by Year (2000–2025)
Kalbe Farma Tbk PT asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Kalbe Farma Tbk PT.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.37% | Rp1.96 Trillion ≈ $114.57 Million |
Rp30.70 Trillion ≈ $1.80 Billion |
-4.61pp |
| 2024-12-31 | 10.98% | Rp3.23 Trillion ≈ $189.32 Million |
Rp29.43 Trillion ≈ $1.72 Billion |
+3.30pp |
| 2023-12-31 | 7.68% | Rp2.08 Trillion ≈ $121.77 Million |
Rp27.06 Trillion ≈ $1.59 Billion |
-1.35pp |
| 2022-12-31 | 9.03% | Rp2.46 Trillion ≈ $144.18 Million |
Rp27.24 Trillion ≈ $1.60 Billion |
-4.93pp |
| 2021-12-31 | 13.96% | Rp3.58 Trillion ≈ $209.93 Million |
Rp25.67 Trillion ≈ $1.50 Billion |
+0.35pp |
| 2020-12-31 | 13.61% | Rp3.07 Trillion ≈ $179.97 Million |
Rp22.56 Trillion ≈ $1.32 Billion |
+2.48pp |
| 2019-12-31 | 11.13% | Rp2.26 Trillion ≈ $132.15 Million |
Rp20.26 Trillion ≈ $1.19 Billion |
-2.91pp |
| 2018-12-31 | 14.03% | Rp2.55 Trillion ≈ $149.23 Million |
Rp18.15 Trillion ≈ $1.06 Billion |
+1.26pp |
| 2017-12-31 | 12.78% | Rp2.12 Trillion ≈ $124.39 Million |
Rp16.62 Trillion ≈ $973.65 Million |
-3.45pp |
| 2016-12-31 | 16.22% | Rp2.47 Trillion ≈ $144.75 Million |
Rp15.23 Trillion ≈ $892.18 Million |
+15.09pp |
| 2015-12-31 | 1.14% | Rp155.75 Billion ≈ $9.13 Million |
Rp13.70 Trillion ≈ $802.56 Million |
-0.47pp |
| 2014-12-31 | 1.60% | Rp199.39 Billion ≈ $11.68 Million |
Rp12.43 Trillion ≈ $728.06 Million |
-0.05pp |
| 2013-12-31 | 1.66% | Rp187.74 Billion ≈ $11.00 Million |
Rp11.32 Trillion ≈ $663.02 Million |
-0.77pp |
| 2012-12-31 | 2.43% | Rp229.12 Billion ≈ $13.43 Million |
Rp9.42 Trillion ≈ $551.85 Million |
+1.06pp |
| 2011-12-31 | 1.38% | Rp113.87 Billion ≈ $6.67 Million |
Rp8.27 Trillion ≈ $484.86 Million |
+1.30pp |
| 2010-12-31 | 0.08% | Rp5.32 Billion ≈ $311.49K |
Rp7.03 Trillion ≈ $412.08 Million |
-0.89pp |
| 2009-12-31 | 0.97% | Rp62.60 Billion ≈ $3.67 Million |
Rp6.48 Trillion ≈ $379.85 Million |
-1.22pp |
| 2008-12-31 | 2.19% | Rp124.75 Billion ≈ $7.31 Million |
Rp5.70 Trillion ≈ $334.22 Million |
-1.23pp |
| 2007-12-31 | 3.42% | Rp175.83 Billion ≈ $10.30 Million |
Rp5.14 Trillion ≈ $301.08 Million |
-2.19pp |
| 2006-12-31 | 5.62% | Rp259.70 Billion ≈ $15.22 Million |
Rp4.62 Trillion ≈ $270.98 Million |
-13.44pp |
| 2005-12-31 | 19.06% | Rp882.99 Billion ≈ $51.74 Million |
Rp4.63 Trillion ≈ $271.50 Million |
-17.51pp |
| 2004-12-31 | 36.57% | Rp1.10 Trillion ≈ $64.65 Million |
Rp3.02 Trillion ≈ $176.78 Million |
+6.24pp |
| 2003-12-31 | 30.33% | Rp742.67 Billion ≈ $43.52 Million |
Rp2.45 Trillion ≈ $143.47 Million |
+15.45pp |
| 2002-12-31 | 14.88% | Rp299.97 Billion ≈ $17.58 Million |
Rp2.02 Trillion ≈ $118.10 Million |
+13.48pp |
| 2001-12-31 | 1.41% | Rp26.39 Billion ≈ $1.55 Million |
Rp1.88 Trillion ≈ $110.00 Million |
-5.44pp |
| 2000-12-31 | 6.84% | Rp120.31 Billion ≈ $7.05 Million |
Rp1.76 Trillion ≈ $103.00 Million |
-- |
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devi… Read more